![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SERINC5 |
Gene summary for SERINC5 |
![]() |
Gene information | Species | Human | Gene symbol | SERINC5 | Gene ID | 256987 |
Gene name | serine incorporator 5 | |
Gene Alias | C5orf12 | |
Cytomap | 5q14.1 | |
Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q86VE9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
256987 | SERINC5 | CCI_1 | Human | Cervix | CC | 4.05e-05 | 8.22e-01 | 0.528 |
256987 | SERINC5 | CCI_2 | Human | Cervix | CC | 6.50e-18 | 1.79e+00 | 0.5249 |
256987 | SERINC5 | CCI_3 | Human | Cervix | CC | 4.68e-14 | 1.13e+00 | 0.516 |
256987 | SERINC5 | HTA11_1938_2000001011 | Human | Colorectum | AD | 3.04e-06 | 5.59e-01 | -0.0811 |
256987 | SERINC5 | HTA11_78_2000001011 | Human | Colorectum | AD | 8.35e-04 | 5.44e-01 | -0.1088 |
256987 | SERINC5 | HTA11_347_2000001011 | Human | Colorectum | AD | 8.12e-24 | 8.79e-01 | -0.1954 |
256987 | SERINC5 | HTA11_9341_2000001011 | Human | Colorectum | SER | 2.67e-03 | -5.49e-01 | -0.00410000000000005 |
256987 | SERINC5 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.02e-02 | 4.38e-01 | 0.096 |
256987 | SERINC5 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 1.23e-06 | 8.65e-01 | 0.3487 |
256987 | SERINC5 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 6.71e-08 | 6.48e-01 | 0.281 |
256987 | SERINC5 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.77e-06 | 8.09e-01 | 0.3859 |
256987 | SERINC5 | A002-C-010 | Human | Colorectum | FAP | 2.69e-03 | 1.43e-01 | 0.242 |
256987 | SERINC5 | A015-C-203 | Human | Colorectum | FAP | 3.42e-36 | -4.53e-01 | -0.1294 |
256987 | SERINC5 | A015-C-204 | Human | Colorectum | FAP | 2.54e-06 | -4.23e-01 | -0.0228 |
256987 | SERINC5 | A014-C-040 | Human | Colorectum | FAP | 3.71e-03 | -1.08e-01 | -0.1184 |
256987 | SERINC5 | A002-C-201 | Human | Colorectum | FAP | 1.46e-12 | -2.52e-01 | 0.0324 |
256987 | SERINC5 | A001-C-119 | Human | Colorectum | FAP | 2.96e-08 | -3.49e-01 | -0.1557 |
256987 | SERINC5 | A001-C-108 | Human | Colorectum | FAP | 4.08e-20 | -3.76e-01 | -0.0272 |
256987 | SERINC5 | A002-C-021 | Human | Colorectum | FAP | 4.72e-09 | 3.62e-01 | 0.1171 |
256987 | SERINC5 | A002-C-205 | Human | Colorectum | FAP | 6.80e-29 | -5.24e-01 | -0.1236 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00096158 | Cervix | CC | response to virus | 73/2311 | 367/18723 | 2.22e-05 | 3.95e-04 | 73 |
GO:00516072 | Cervix | CC | defense response to virus | 46/2311 | 265/18723 | 1.04e-02 | 4.97e-02 | 46 |
GO:01405462 | Cervix | CC | defense response to symbiont | 46/2311 | 265/18723 | 1.04e-02 | 4.97e-02 | 46 |
GO:0006575 | Colorectum | AD | cellular modified amino acid metabolic process | 59/3918 | 188/18723 | 4.80e-04 | 5.27e-03 | 59 |
GO:0006520 | Colorectum | AD | cellular amino acid metabolic process | 81/3918 | 284/18723 | 1.37e-03 | 1.19e-02 | 81 |
GO:0006650 | Colorectum | AD | glycerophospholipid metabolic process | 83/3918 | 306/18723 | 5.40e-03 | 3.55e-02 | 83 |
GO:0006644 | Colorectum | AD | phospholipid metabolic process | 101/3918 | 383/18723 | 5.80e-03 | 3.67e-02 | 101 |
GO:0046486 | Colorectum | SER | glycerolipid metabolic process | 82/2897 | 392/18723 | 2.26e-03 | 2.17e-02 | 82 |
GO:00066441 | Colorectum | SER | phospholipid metabolic process | 79/2897 | 383/18723 | 3.94e-03 | 3.24e-02 | 79 |
GO:00065201 | Colorectum | SER | cellular amino acid metabolic process | 61/2897 | 284/18723 | 4.20e-03 | 3.41e-02 | 61 |
GO:00066501 | Colorectum | SER | glycerophospholipid metabolic process | 64/2897 | 306/18723 | 6.41e-03 | 4.60e-02 | 64 |
GO:00065751 | Colorectum | MSS | cellular modified amino acid metabolic process | 55/3467 | 188/18723 | 2.16e-04 | 3.01e-03 | 55 |
GO:0046394 | Colorectum | MSS | carboxylic acid biosynthetic process | 76/3467 | 314/18723 | 6.71e-03 | 4.38e-02 | 76 |
GO:0016053 | Colorectum | MSS | organic acid biosynthetic process | 76/3467 | 316/18723 | 7.88e-03 | 4.84e-02 | 76 |
GO:1901605 | Colorectum | MSI-H | alpha-amino acid metabolic process | 26/1319 | 195/18723 | 1.26e-03 | 2.02e-02 | 26 |
GO:00065752 | Colorectum | MSI-H | cellular modified amino acid metabolic process | 25/1319 | 188/18723 | 1.61e-03 | 2.39e-02 | 25 |
GO:0008652 | Colorectum | MSI-H | cellular amino acid biosynthetic process | 13/1319 | 76/18723 | 2.35e-03 | 3.12e-02 | 13 |
GO:1901607 | Colorectum | MSI-H | alpha-amino acid biosynthetic process | 12/1319 | 68/18723 | 2.60e-03 | 3.41e-02 | 12 |
GO:00463941 | Colorectum | MSI-H | carboxylic acid biosynthetic process | 36/1319 | 314/18723 | 2.68e-03 | 3.48e-02 | 36 |
GO:00160531 | Colorectum | MSI-H | organic acid biosynthetic process | 36/1319 | 316/18723 | 2.98e-03 | 3.78e-02 | 36 |
Page: 1 2 3 4 5 6 7 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa03250 | Colorectum | MSS | Viral life cycle - HIV-1 | 23/1875 | 63/8465 | 6.55e-03 | 2.64e-02 | 1.62e-02 | 23 |
hsa032501 | Colorectum | MSS | Viral life cycle - HIV-1 | 23/1875 | 63/8465 | 6.55e-03 | 2.64e-02 | 1.62e-02 | 23 |
hsa032509 | Esophagus | ESCC | Viral life cycle - HIV-1 | 54/4205 | 63/8465 | 2.01e-09 | 2.17e-08 | 1.11e-08 | 54 |
hsa0325014 | Esophagus | ESCC | Viral life cycle - HIV-1 | 54/4205 | 63/8465 | 2.01e-09 | 2.17e-08 | 1.11e-08 | 54 |
hsa032502 | Liver | HCC | Viral life cycle - HIV-1 | 46/4020 | 63/8465 | 3.25e-05 | 1.88e-04 | 1.04e-04 | 46 |
hsa0325011 | Liver | HCC | Viral life cycle - HIV-1 | 46/4020 | 63/8465 | 3.25e-05 | 1.88e-04 | 1.04e-04 | 46 |
hsa032508 | Oral cavity | OSCC | Viral life cycle - HIV-1 | 45/3704 | 63/8465 | 7.62e-06 | 3.59e-05 | 1.83e-05 | 45 |
hsa0325013 | Oral cavity | OSCC | Viral life cycle - HIV-1 | 45/3704 | 63/8465 | 7.62e-06 | 3.59e-05 | 1.83e-05 | 45 |
hsa032506 | Oral cavity | NEOLP | Viral life cycle - HIV-1 | 16/1112 | 63/8465 | 6.21e-03 | 2.33e-02 | 1.46e-02 | 16 |
hsa032507 | Oral cavity | NEOLP | Viral life cycle - HIV-1 | 16/1112 | 63/8465 | 6.21e-03 | 2.33e-02 | 1.46e-02 | 16 |
hsa032504 | Prostate | BPH | Viral life cycle - HIV-1 | 24/1718 | 63/8465 | 8.32e-04 | 3.98e-03 | 2.46e-03 | 24 |
hsa0325012 | Prostate | BPH | Viral life cycle - HIV-1 | 24/1718 | 63/8465 | 8.32e-04 | 3.98e-03 | 2.46e-03 | 24 |
hsa0325021 | Prostate | Tumor | Viral life cycle - HIV-1 | 25/1791 | 63/8465 | 6.13e-04 | 3.07e-03 | 1.91e-03 | 25 |
hsa032503 | Prostate | Tumor | Viral life cycle - HIV-1 | 25/1791 | 63/8465 | 6.13e-04 | 3.07e-03 | 1.91e-03 | 25 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SERINC5 | SNV | Missense_Mutation | novel | c.634N>A | p.Gly212Ser | p.G212S | Q86VE9 | protein_coding | tolerated(0.15) | benign(0.118) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SERINC5 | SNV | Missense_Mutation | novel | c.230N>C | p.Lys77Thr | p.K77T | Q86VE9 | protein_coding | tolerated(0.54) | benign(0.419) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
SERINC5 | SNV | Missense_Mutation | rs539325635 | c.142N>A | p.Val48Ile | p.V48I | Q86VE9 | protein_coding | tolerated(0.79) | benign(0.011) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
SERINC5 | insertion | Frame_Shift_Ins | novel | c.207_208insT | p.Glu70Ter | p.E70* | Q86VE9 | protein_coding | TCGA-A5-A0GW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
SERINC5 | insertion | Nonsense_Mutation | novel | c.501_502insTGAAAT | p.Gly167_Ile168insTer | p.G167_I168ins* | Q86VE9 | protein_coding | TCGA-B5-A11V-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
SERINC5 | SNV | Missense_Mutation | c.907N>T | p.Gly303Cys | p.G303C | Q86VE9 | protein_coding | deleterious(0.02) | probably_damaging(0.939) | TCGA-05-4382-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
SERINC5 | SNV | Missense_Mutation | c.436N>T | p.Asp146Tyr | p.D146Y | Q86VE9 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-50-5933-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | carboplatin | CR | |
SERINC5 | SNV | Missense_Mutation | c.208G>C | p.Glu70Gln | p.E70Q | Q86VE9 | protein_coding | tolerated(0.21) | benign(0.081) | TCGA-50-5946-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
SERINC5 | SNV | Missense_Mutation | novel | c.1215G>A | p.Met405Ile | p.M405I | Q86VE9 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-55-A48Y-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | CR |
SERINC5 | SNV | Missense_Mutation | rs759732415 | c.610N>G | p.Ile204Val | p.I204V | Q86VE9 | protein_coding | tolerated(0.96) | benign(0.005) | TCGA-86-A4JF-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | unknown | PD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |